NCT05693090View on ClinicalTrials.gov

Tipifarnib and Osimertinib in EGFR-mutated Non-Small Cell Lung Cancer

PHASE1WithdrawnINTERVENTIONAL
0
Timeline

Start Date

February 1, 2023

Primary Completion Date

July 27, 2027

Study Completion Date

July 27, 2027

Conditions
NSCLC
Interventions
DRUG

Tipifarnib

Oral administration

DRUG

Osimertinib

Oral administration

Trial Locations (2)

95403

Providence Medical Group, Santa Rosa

07450

The Valley Hospital, Ridgewood

Sponsors
All Listed Sponsors
lead

Kura Oncology, Inc.

INDUSTRY